AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1878235 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (Group 1, n = 15)
Number of subjects: 45
Study 1878235 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with lidocaine 1% (Group 2, n = 15)
Number of subjects: 45
Study 1878235 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% with fentanyl 50 micrograms in 10 ml of saline (Group 3, n = 15)
Number of subjects: 45
Study 6308283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 92
Study 6308283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31827320 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.5 mg/kg)
Number of subjects: 32
Study 31827320 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine (1 mg/kg)
Number of subjects: 32
Study 28398852 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer intervention
Number of subjects: 59
Study 28398852 — intervention group
Group type: COMPARATOR
Intervention: Professional intervention
Number of subjects: 59
Study 25683315 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin type A (BTX‐A) injection
Number of subjects: 16
Study 25683315 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) injection
Number of subjects: 16
Study 24288083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 12
Study 22100966 — intervention group
Group type: COMPARATOR
Intervention: Diabetic (DM) group
Number of subjects: 147
Study 22100966 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance (IGT) group
Number of subjects: 147
Study 22100966 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 147
Study 20479765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine (TE) 2.0 mg daily for 7 days followed by 1.0 mg daily for 7 days
Number of subjects: 32
Study 20479765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine (TE)
Number of subjects: 32
Study 20479765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study 17401036 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychoeducation plus 16 problem-solving group sessions
Number of subjects: 176
Study 17401036 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 176
Study 15865497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (32 ounces/day of a beverage containing 27% cranberry juice)
Number of subjects: 50
Study 15865497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15865497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 50
Study 12028165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin group (2.5 mg daily to 5 mg three times a day)
Number of subjects: 105
Study 12028165 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training
Number of subjects: 105
Study 12028165 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 105
Study 9607264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily with diet
Number of subjects: 60
Study 9607264 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 60
Study 7899538 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg bid)
Number of subjects: 31
Study 7899538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2223370 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.1 mg kg‐1
Number of subjects: 40
Study 2223370 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 4.0 micrograms kg‐1
Number of subjects: 40
Study 2223370 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of morphine and alfentanil
Number of subjects: 40
Study 2223370 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 40
Study 75397 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal exposure to agoraphobic film
Number of subjects: 15
Study 75397 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal exposure to agoraphobic film
Number of subjects: 15
Study 75397 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank screen)
Number of subjects: 15
Study 31752751 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intervention (weekly emails and social media posts)
Number of subjects: 557
Study 31752751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 557
Study 28974628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical carotid dissection
Number of subjects: 295
Study 28974628 — intervention group
Group type: COMPARATOR
Intervention: Cervical carotid atherosclerotic cause
Number of subjects: 295
Study 25931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane for inhalation anesthesia (I group)
Number of subjects: 416
Study 25931799 — intervention group
Group type: COMPARATOR
Intervention: Propofol for total intravenous anesthesia (T group)
Number of subjects: 416
Study 25931799 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 416
Study 23663213 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (community program)
Number of subjects: 69
Study 23663213 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 23663213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 23663213 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 69
Study 23663213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to exercise
Number of subjects: 69
Study 21737584 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP)
Number of subjects: 366
Study 21737584 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 366
Study 19936513 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 12
Study 19936513 — intervention group
Group type: COMPARATOR
Intervention: Coffee
Number of subjects: 12
Study 19936513 — intervention group
Group type: COMPARATOR
Intervention: Yerba mate
Number of subjects: 12
Study 19936513 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 16298235 — intervention group
Group type: EXPERIMENTAL
Intervention: CJD patients with high total tau (t-tau) levels
Number of subjects: 3
Study 16298235 — intervention group
Group type: EXPERIMENTAL
Intervention: CJD patients with low phosphorylated tau at threonine 231 (p-tau231) levels
Number of subjects: 3
Study 16298235 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tau (t-tau) diagnostic accuracy
Number of subjects: 3
Study 16298235 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylated tau at threonine 231 (p-tau231) diagnostic accuracy
Number of subjects: 3
Study 16298235 — intervention group
Group type: EXPERIMENTAL
Intervention: p-tau231/t-tau ratio diagnostic accuracy
Number of subjects: 3
Study 14664679 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10757578 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB)
Number of subjects: 44
Study 10757578 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 44
Study 10757578 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia and Paracervical block (PCB)
Number of subjects: 44
Study 8930426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide three times daily
Number of subjects: 75
Study 8930426 — intervention group
Group type: COMPARATOR
Intervention: 2% pilocarpine four times daily
Number of subjects: 75
Study 1551720 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g four times a day
Number of subjects: 100
Study 1551720 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 100
Study 4002788 — intervention group
Group type: COMPARATOR
Intervention: muzolimine 20 mg
Number of subjects: 10
Study 4002788 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine 30 mg
Number of subjects: 10
Study 4002788 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine 40 mg
Number of subjects: 10
Study 4002788 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 30931801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain placement
Number of subjects: 6858
Study 30931801 — intervention group
Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 6858
Study 28988160 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 511
Study 28988160 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 511
Study 27167763 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental book reading (frequency)
Number of subjects: 0
Study 27167763 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start program
Number of subjects: 0
Study 27167763 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster parents in Head Start
Number of subjects: 0
Study 24904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen B
Number of subjects: 249
Study 24904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen C
Number of subjects: 249
Study 24904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome
Number of subjects: 249
Study 24904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 249
Study 24904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance phase
Number of subjects: 249
Study 24904116 — intervention group
Group type: COMPARATOR
Intervention: Overall IRM
Number of subjects: 249
Study 22407057 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h interval clamping (group B)
Number of subjects: 100
Study 22407057 — intervention group
Group type: COMPARATOR
Intervention: non‐clamping (group A)
Number of subjects: 100
Study 19954777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance physical exercise (14 days of cross-country skiing, 12-30km per day, ~10h of activity)
Number of subjects: 20
Study 19954777 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (40% of energy derived from fat)
Number of subjects: 20
Study 19954777 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (30% of energy derived from fat)
Number of subjects: 20
Study 19954777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance physical exercise
Number of subjects: 20
Study 18559233 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese drug (TCD) treatment with Huzhang Gout Granule and Jinhuang Ointment in acute stage; Yinlian Gout Granule in intermission.
Number of subjects: 166
Study 18559233 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (WM) treatment with diclofenac sodium dual release enteric-coated capsules in acute stage; benzbromarone or allopurinol in intermission.
Number of subjects: 166
Study 18559233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TCD and WM treatment in acute stage and intermission.
Number of subjects: 166
Study 18559233 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment).
Number of subjects: 166
Study 15612981 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg if body weight >30 kg; 10 mg if <30 kg) given pretransplant and at day 4; Tacrolimus (Tac) administered to obtain blood trough levels of 10-20 ng/ml during the first 2 months and 5-10 ng/ml thereafter; Steroids tapered during the first 6 months and replaced by mycophenolate mofetil (4-600 mg/m² body surface area) depending on previous rejection episodes, infection status, and routine biopsy results.
Number of subjects: 53
Study 15560817 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+Zn
Number of subjects: 10
Study 15560817 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+CPC
Number of subjects: 10
Study 15560817 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+ALC
Number of subjects: 10
Study 15560817 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+NaF
Number of subjects: 10
Study 15560817 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+NO
Number of subjects: 10
Study 15560817 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 10
Study 11422684 — intervention group
Group type: COMPARATOR
Intervention: Palpation tenderness of masticatory muscles
Number of subjects: 67
Study 11422684 — intervention group
Group type: COMPARATOR
Intervention: Combination of palpatory tenderness and clenching habit
Number of subjects: 67
Study 11422684 — intervention group
Group type: COMPARATOR
Intervention: Clenching habit alone
Number of subjects: 67
Study 11422684 — intervention group
Group type: COMPARATOR
Intervention: Negative predictive value of muscle tenderness
Number of subjects: 67
Study 8996129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam (KM): atropine 0.01 mg/kg, midazolam 0.05 mg/kg, ketamine 1.5 mg/kg
Number of subjects: 22
Study 8996129 — intervention group
Group type: COMPARATOR
Intervention: Meperidine-midazolam (MM): meperidine 2 mg/kg, midazolam 0.1 mg/kg
Number of subjects: 22
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 1 microgram/kg
Number of subjects: 18
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 2 micrograms/kg
Number of subjects: 18
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mivazerol 3 micrograms/kg
Number of subjects: 18
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mivazerol 800 micrograms
Number of subjects: 18
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mivazerol 1200 micrograms
Number of subjects: 18
Study 7912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mivazerol 1600 micrograms
Number of subjects: 18
Study 3520390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline and clenbuterol combination
Number of subjects: 0
Study 3520390 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 0
Study 3520390 — intervention group
Group type: COMPARATOR
Intervention: Clenbuterol
Number of subjects: 0
Study 31910393 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 8 weeks, 7 days per week, twice daily, using POWERbreathe KH1, starting at 50% of maximum inspiratory pressure with progressively increasing load
Number of subjects: 47
Study 31910393 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 47
Study 28741729 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hard palate closure (EHPC) at 12 months
Number of subjects: 126
Study 28741729 — intervention group
Group type: COMPARATOR
Intervention: Late hard palate closure (LHPC) at 36 months
Number of subjects: 126
Study 28741729 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without CP)
Number of subjects: 126
Study 28741729 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (within UCLP groups)
Number of subjects: 126
Study 27436668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 0
Study 24958577 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4‐BPT) and methacholine bronchial provocation test (MCh‐BPT)
Number of subjects: 83
Study 24958577 — intervention group
Group type: EXPERIMENTAL
Intervention: Log10RDR
Number of subjects: 83
Study 24958577 — intervention group
Group type: EXPERIMENTAL
Intervention: RDR and PD20FEV1 combination
Number of subjects: 83
Study 24958577 — intervention group
Group type: EXPERIMENTAL
Intervention: RDR (≤ 25th percentile)
Number of subjects: 83
Study 22677927 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR)
Number of subjects: 6
Study 22677927 — intervention group
Group type: COMPARATOR
Intervention: Control (CNTRL)
Number of subjects: 6
Study 20546210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil at ED 20
Number of subjects: 115
Study 20546210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil at ED 40
Number of subjects: 115
Study 20546210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sufentanil with ropivacaine
Number of subjects: 115
Study 20546210 — intervention group
Group type: COMPARATOR
Intervention: Control group (ropivacaine alone)
Number of subjects: 115
Study 18262758 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 475
Study 18262758 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 475
Study 18262758 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate/megestrol acetate plus pharmacologic nutritional support plus L-carnitine plus thalidomide
Number of subjects: 475
Study 18262758 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic nutritional support containing eicosapentaenoic acid
Number of subjects: 475
Study 18262758 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate/megestrol acetate
Number of subjects: 475
Study 16874160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum C3 levels
Number of subjects: 1200
Study 12791112 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 1.0 ml.kg‐1 body weight (BW) bupivacaine 0.25%
Number of subjects: 58
Study 12791112 — intervention group
Group type: COMPARATOR
Intervention: Wound instillation with 0.2 ml.kg‐1 BW bupivacaine 0.5%
Number of subjects: 58
Study 11020743 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine + Nitroglycerin
Number of subjects: 48
Study 11020743 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 48
Study 11020743 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline + Placebo)
Number of subjects: 48
Study 8806245 — intervention group
Group type: EXPERIMENTAL
Intervention: ethamsylate 500 mg six hourly
Number of subjects: 76
Study 8806245 — intervention group
Group type: EXPERIMENTAL
Intervention: mefenamic acid 500 mg eight hourly
Number of subjects: 76
Study 8806245 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g six hourly
Number of subjects: 76
Study 1459517 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine (100 mg/day)
Number of subjects: 402
Study 1459517 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (800 mg/day)
Number of subjects: 402
Study 1459517 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine (75 mg/day)
Number of subjects: 402
Study 1459517 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 402
Study 3901683 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose group (HDG) received 120‐160 mg furosemide daily for six weeks
Number of subjects: 83
Study 3901683 — intervention group
Group type: COMPARATOR
Intervention: Low dose group (LDG) received 20‐40 mg furosemide daily for six weeks
Number of subjects: 83
Study 30920098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 0.2 mL of vitamin D3 (300,000 IU) into the base of mother wart for two sessions
Number of subjects: 50
Study 30920098 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 50
Study 30179211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (25 Hz)
Number of subjects: 36
Study 30179211 — intervention group
Group type: COMPARATOR
Intervention: Control (sham vibration)
Number of subjects: 36
Study 27412942 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC), 3 capsules three times daily for 12 weeks
Number of subjects: 56
Study 27412942 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC)
Number of subjects: 56
Study 27412942 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 4 tablets two times daily for 12 weeks
Number of subjects: 56
Study 25419883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 24
Study 25419883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22611998 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of lidocaine
Number of subjects: 60
Study 22611998 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of lidocaine
Number of subjects: 60
Study 22611998 — intervention group
Group type: COMPARATOR
Intervention: Isotonic normal saline
Number of subjects: 60
Study 22611998 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vs 200 mg lidocaine
Number of subjects: 60
Study 22611998 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 20140830 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 120
Study 20140830 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic accuracy studies
Number of subjects: 120
Study 17565578 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-ST
Number of subjects: 430
Study 17565578 — intervention group
Group type: COMPARATOR
Intervention: SRL-CsA-ST
Number of subjects: 430
Study 17565578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 430
Study 16095507 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of 5‐methyl‐tetrahydrofolate
Number of subjects: 44
Study 16095507 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 44
Study 12466345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 60
Study 12466345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10072746 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced program (standard program plus an educational booklet/telephone call)
Number of subjects: 5042
Study 10072746 — intervention group
Group type: COMPARATOR
Intervention: Standard program (including rectal examination, fecal occult blood testing, and flexible sigmoidoscopy)
Number of subjects: 5042
Study 8533868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (NLA): 7.1 mg droperidol and 0.008 mg/kg body weight fentanyl
Number of subjects: 1318
Study 8533868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with propofol (IVA): 493.4 mg propofol and 0.004 mg/kg body weight fentanyl
Number of subjects: 1318